- Home
- ANNX
ANNX
Annexon Inc.
as 01-17-2025 4:00pm EST
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 553.2M | IPO Year: | 2020 |
| Target Price: | $15.80 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.86 - $8.40 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Annexon Inc. (ANNX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Carson William H. | ANNX | Director | Dec 2 '24 | Buy | $5.33 | 3,200 | $17,056.00 | 25,600 |
Latest Annexon Inc. News
ANNX Breaking Stock News: Dive into ANNX Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year
GlobeNewswire
9 days ago
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones
GlobeNewswire
12 days ago
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
a month ago
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
GlobeNewswire
a month ago
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting
Pharma Voice
2 months ago
The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate.
GlobeNewswire
2 months ago
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Compare ANNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANNX Annexon Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.